Silibinin to Treat Cancer - Quick Reference Sheet
evipedia.ai ← Back

Silibinin to Treat Cancer

Created on 07/28/2026 – Quick Reference based on Evidence Review created using AI4L / Opus 4.8 – Audit

Silibinin, the main compound in milk thistle, is cheap, oral, and very well tolerated. Its best human support is protecting the liver, heart, skin, and gut during chemotherapy and radiation. Directly shrinking tumors, including lung cancer that has spread to the brain, remains early and unproven; the main concern is possible interference with standard cancer treatment. (Full Review)

Protocol

Formulation
Phospholipid-complexed silibinin
Silibinin bound to phosphatidylcholine delivers far higher blood levels than standard silymarin; preferred for oncology use
Dose
200–400 mg silymarin, 2–3× daily
Standardized extract (70–80% silymarin); bioavailability-enhanced forms used at higher silibinin doses in cancer settings
Timing
With meals, split dosing
Divided 2–3× daily to maintain exposure given the short (~6 h) half-life
Time to effect
Liver & biomarker effects
Weeks to a few months
Liver enzymes, glucose, PSA/IGF-1 shift gradually
Perceptible effect
None immediate
No rapidly noticeable effect
Anti-tumor effect
Unproven in humans
Human anti-tumor benefit remains unproven

Benefits

Contraindications
  • Known allergy to Asteraceae-family plants
  • Pregnancy or breastfeeding
  • Active chemotherapy or narrow-therapeutic-index drugs without oncologist oversight
  • Significant biliary obstruction
    •
Key Interactions
  • Chemotherapy agents (doxorubicin, cisplatin, irinotecan, taxanes)
  • Prescription CYP3A4 substrates (statins e.g. simvastatin, immunosuppressants e.g. tacrolimus, some kinase inhibitors)
  • OTC drugs cleared by glucuronidation (acetaminophen/paracetamol)
  • Antidiabetic drugs and supplements (metformin, sulfonylureas, berberine, alpha-lipoic acid)
  • Anticoagulant/antiplatelet agents and additive supplements (warfarin, fish oil, high-dose vitamin E)
    •

Risk & Side Effects

  • High: Mild gastrointestinal disturbances
    •
  • Medium: Drug interactions and possible alteration of chemotherapy efficacy
    •
  • Low: Allergic and hypersensitivity reactions; blood glucose lowering
    •
  • Speculative: Estrogenic activity in hormone-sensitive cancers
    •

Monitoring

Marker Target Why
ALT (alanine aminotransferase) 10–25 U/L Tracks liver-cell stress and the hepatoprotective effect
AST (aspartate aminotransferase) 10–25 U/L Complements ALT for liver injury during chemotherapy
Total bilirubin 0.3–1.0 mg/dL Reflects liver clearance capacity
Fasting glucose 75–90 mg/dL Detects additive glucose lowering in those on antidiabetic drugs
PSA (prostate-specific antigen) < 2.5 ng/mL (context-dependent) Surrogate marker of activity in prostate cancer use
IGF-1 (insulin-like growth factor 1) Mid-to-lower age-adjusted reference range Growth-signaling marker silibinin may lower

Cadence: Liver enzymes and glucose at ~4 weeks, then every 3 months during continued use, aligning with chemotherapy cycles; prostate markers (PSA, IGF-1) every 3–6 months

Qualitative Assessment

  • Energy levels and treatment-related fatigue
  • Appetite and gastrointestinal comfort (nausea, stool changes)
  • Skin condition during radiotherapy (dermatitis severity)
  • Mouth comfort during chemotherapy (mucositis)
  • General sense of tolerability of the concurrent cancer treatment
Not medical advice. Educational distillation of a single evidence review. Confirm any decision with a qualified clinician, especially in the presence of prescription drugs or chronic conditions.